Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar sodium in PCOS with Type 2 Diabetes
NCT05760677Phase 1Unknown
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of chiglitazar in polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Affiliated Hospital of Nantong University. Primary endpoints: Change of plasma glucose at 12 weeks and The recovery of menstrual cycle at 12 weeks. Status: unknown.
02
Drugs
chiglitazar
03
Conditions
polycystic ovary syndrome (PCOS)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05760677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760677.